Table 2.

Univariate analysis of factors associated with response, PFS, and OS

ORRPPFSPOSP
Age >70 y 29% vs 36% .393 4.9 vs 5 .667 8.4 vs 14.3 .761 
Hemoglobin <10 g/dL 26% vs 36% .221 4 vs 5.5 .015 7.8 vs 22.8 <.001 
Platelets <100 × 109/L 20% vs 37.5% .055 4 vs 5.4 .005 7.2 vs 14.4 <.001 
LDH > ULN 35% vs 31% .636 3.7 vs 6 .001 7.9 vs 16.6 <.001 
Calcium >10.5 mg/dL 34% vs 30% .734 2.85 vs 4.9 .016 7.2 vs 14.3 <.001 
eGFR <60 mL/min/1.73 m2 34% vs 32% .806 4.8 vs 5.1 .597 9.3 vs 12.8 .650 
ISS 1 vs 2 vs 3 35% vs 30.5% .552 5.8 vs 3.7 .008 8 vs 16.2 .028 
Last dose of lenalidomide 5-15 mg vs 25 mg 38.5% vs 30.5% .329 4.9 vs 5 .929 11.9 vs 12.8 .194 
Dexamethasone dose 0 vs <80 mg vs 160 mg 78% vs 33% vs 31% .015 20.6 vs 4 vs 4.8 .03 NR vs 9 vs 11.7 .077 
Lenalidomide vs bortezomib/other PI vs chemo before Pd 32% vs 37% vs 24% .546 4.6 vs 5.9 vs 4.1 .491 13.4 vs 11.9 vs 7.4 .189 
Disease refractory to bortezomib 30% vs 42% .158 4.9 vs 5.5 .112 11.4 vs 23.1 .109 
1-2 vs 3 vs >3 lines of prior therapy 42% vs 37% 27% .306 2.8 vs 4.8 vs 6 .919 16 vs 12 vs 11.8 .727 
Del17p* 36% vs 37% .991 4.6 vs 11.5 .413 46 vs 12.2 .233 
T(4;14)** 42% vs 33% .591 5.1 vs 4.1 .973 7.5 vs 23 .074 
Amp1q21* 39% vs 37% .866 5.1 vs 4.6 .542 7.1 vs 16.5 .400 
Any high-risk cytogenetics*,† 42% vs 32% .386 4 vs 6.5 .455 22.8 vs 16.5 .850 
Duration of last lenalidomide therapy <12 mo 27% vs 44% .03 3.2 vs 7.8 .023 7.9 vs 16.5 .005 
IMiD-free interval <18 mo 23% vs 65% <.001 3.9 vs 10.3 .003 9.3 vs 27.1 .008 
ORRPPFSPOSP
Age >70 y 29% vs 36% .393 4.9 vs 5 .667 8.4 vs 14.3 .761 
Hemoglobin <10 g/dL 26% vs 36% .221 4 vs 5.5 .015 7.8 vs 22.8 <.001 
Platelets <100 × 109/L 20% vs 37.5% .055 4 vs 5.4 .005 7.2 vs 14.4 <.001 
LDH > ULN 35% vs 31% .636 3.7 vs 6 .001 7.9 vs 16.6 <.001 
Calcium >10.5 mg/dL 34% vs 30% .734 2.85 vs 4.9 .016 7.2 vs 14.3 <.001 
eGFR <60 mL/min/1.73 m2 34% vs 32% .806 4.8 vs 5.1 .597 9.3 vs 12.8 .650 
ISS 1 vs 2 vs 3 35% vs 30.5% .552 5.8 vs 3.7 .008 8 vs 16.2 .028 
Last dose of lenalidomide 5-15 mg vs 25 mg 38.5% vs 30.5% .329 4.9 vs 5 .929 11.9 vs 12.8 .194 
Dexamethasone dose 0 vs <80 mg vs 160 mg 78% vs 33% vs 31% .015 20.6 vs 4 vs 4.8 .03 NR vs 9 vs 11.7 .077 
Lenalidomide vs bortezomib/other PI vs chemo before Pd 32% vs 37% vs 24% .546 4.6 vs 5.9 vs 4.1 .491 13.4 vs 11.9 vs 7.4 .189 
Disease refractory to bortezomib 30% vs 42% .158 4.9 vs 5.5 .112 11.4 vs 23.1 .109 
1-2 vs 3 vs >3 lines of prior therapy 42% vs 37% 27% .306 2.8 vs 4.8 vs 6 .919 16 vs 12 vs 11.8 .727 
Del17p* 36% vs 37% .991 4.6 vs 11.5 .413 46 vs 12.2 .233 
T(4;14)** 42% vs 33% .591 5.1 vs 4.1 .973 7.5 vs 23 .074 
Amp1q21* 39% vs 37% .866 5.1 vs 4.6 .542 7.1 vs 16.5 .400 
Any high-risk cytogenetics*,† 42% vs 32% .386 4 vs 6.5 .455 22.8 vs 16.5 .850 
Duration of last lenalidomide therapy <12 mo 27% vs 44% .03 3.2 vs 7.8 .023 7.9 vs 16.5 .005 
IMiD-free interval <18 mo 23% vs 65% <.001 3.9 vs 10.3 .003 9.3 vs 27.1 .008 
*

Available in 64 patients.

†

Defined as presence of any of t(4,14) or t(14,16) del17p.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal